Clinical Trials
3 trialsNCT07455617 2026-04-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Recruiting
NCT04055792 2023-06-28
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Henan Cancer Hospital
Phase 2 Completed
NCT04398927 2021-02-04
Systemic Chemotherapy Plus PD-1 for Metastasis ICC
Sun Yat-sen University
Phase 2 Withdrawn